What happened with AVR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Anteris Technologies Global Corp. is focused on developing DurAVR THV, a replacement aortic valve delivered through a catheter rather than open-heart surgery. It molds bovine heart-sac tissue into a single-piece valve, treats it with its ADAPT process to limit calcium buildup, and mounts it inside a metal frame. Its ComASUR Delivery System positions and deploys the valve. DurAVR remains in clinical trials and needs regulatory approval before commercial sale.
Its small revenue base has come from regenerative tissue products, historically sold mainly to 4C and LeMaitre Vascular. 4C bought ADAPT tissue for mitral- and tricuspid-valve devices and licensed related sterilization methods, paying for tissue by individual order with no minimum purchase commitment. The LeMaitre supply arrangement ended in January 2025, with no ongoing revenue expected. After Anteris gave notice of non-renewal, the 4C agreement was scheduled to end in June 2026.
This revenue does not cover research, development and operations. Anteris has financed much of its work by issuing equity and needs additional capital to continue development. Substantial product revenue depends on completing clinical trials, obtaining approval and establishing manufacturing and commercial sales; U.S. commercialization of DurAVR requires FDA premarket approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Edwards Lifesciences sells SAPIEN valves to the same hospital heart teams Anteris targets with DurAVR, making it a direct rival for adoption of valves implanted through a catheter rather than open-heart surgery. Watch Edwards's transcatheter aortic valve replacement (TAVR) sales: they accounted for 74% of its net sales in 2025.
Medtronic competes directly with Anteris in catheter-based aortic valve replacement and also influences it as a shareholder, owning approximately 16.1% of its common stock as of January 22, 2026. Its rights to participate in future share issues, appoint a non-voting board observer and negotiate on certain acquisition proposals make its investment decisions important to Anteris holders; their interests may not align.
Abbott's Navitor valve competes with Anteris's DurAVR for patients needing aortic valve replacement and the hospital heart teams treating them. Both address replacement valves implanted through a catheter, so Navitor is a competing choice for the customers Anteris targets.
Anteris relies on Integer Holdings Corporation's Aran Biomedical subsidiary for knitted materials used in its products; Integer earns revenue by designing and making devices and components for medical-device companies. Watch this supply agreement's renewal: its initial five-year term began in November 2021, and each one-year extension requires both parties' written agreement.
Artivion offers alternatives to Anteris's tissue-based cardiovascular products by selling mechanical heart valves and charging for preservation of human cardiac tissues for implantation. Its On-X valve sales and cardiac-tissue preservation business are the relevant lines to watch, rather than treating all its device revenue as direct competition with DurAVR.
Edwards Lifesciences Corp earningsEW
Edwards Lifesciences' report will show how hospital heart teams are responding to catheter-implanted aortic valves, the market Anteris Technologies Global Corp. is trying to enter.
Focus on Edwards' transcatheter aortic valve replacement (TAVR) sales. Strong sales would show that hospitals continue to adopt these valves, giving Anteris a market with sustained demand as well as an established rival. Weaker sales would point to pressure on adoption, but would not establish Anteris's own demand.
Anteris Technologies Global Corp. earningsThis company
Anteris Technologies Global Corp.'s report will show whether sales of its remaining tissue products are helping fund DurAVR development or leaving it more reliant on outside financing.
Read tissue-product sales alongside research and development spending and operating cash flow. Rising sales of higher-yielding products with controlled spending and cash use would show the existing business is better supporting DurAVR development; weak sales alongside higher spending and cash use would mean more financing pressure.
